Prostate Cancer - Results from #220

Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor. October 3, 2024

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). October 3, 2024

Clarity’s COBRA Study Selected as a Top-Rated Oral Presentation at Prestigious Industry Annual Meeting October 2, 2024

Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer. October 2, 2024

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. October 2, 2024

Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer. October 2, 2024

Novel intraprostatic MR-guided implantation of multidrug-eluting microdevice for testing of systemic therapy agents in situ; Proof of concept in intermediate- and high-risk prostate cancer. October 2, 2024

When is prostate cancer really cancer? October 2, 2024

CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) October 1, 2024

Partial prostatectomy for localized prostate cancer. October 1, 2024

Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy - results from a contemporary National Cancer Database study. October 1, 2024

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). October 1, 2024

The Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer. October 1, 2024

Adverse Health Outcomes 3 Years after Radical Prostatectomy Compared with Men in the General Population: A Study from the Cancer Registry of Norway. October 1, 2024

Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics September 30, 2024

Teleflex’s Barrigel Rectal Spacer to Be Featured in Three Presentations at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting September 30, 2024

Identification of blood lipid markers of docetaxel treatment in prostate cancer patients. September 30, 2024

Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance. September 30, 2024

Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score. September 30, 2024

Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer. September 30, 2024

Page 12 of 1438